Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

1(25%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

75%

Ph phase_2

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

3(75.0%)

Phase 2Efficacy & side effects

1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(2)

Detailed Status

Completed2

Active, not recruiting1

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 13 (75.0%)

Phase 21 (25.0%)

Trials by Status

completed250%

active_not_recruiting125%

not_yet_recruiting125%

Recent Activity

1 active trials

Showing 4 of 4

active_not_recruitingphase_2

Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus

NCT06964087

completedphase_1

1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.

NCT04589403

not_yet_recruitingphase_1

OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis

NCT06669403

completedphase_1

OPT101 in Type 1 Diabetes Patients

NCT05428943

Clinical Trials (4)

Showing 4 of 4 trials

NCT06964087Phase 2

Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus

Active Not Recruiting

NCT04589403Phase 1

1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.

Completed

NCT06669403Phase 1

OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis

Not Yet Recruiting

NCT05428943Phase 1

OPT101 in Type 1 Diabetes Patients

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4